

Drug Use Investigation of ANORO ELLIPTA inhaler (200311)

First published: 02/06/2015

Last updated: 18/04/2024

Study

Finalised

Administrative details

EU PAS number

EUPAS9868

Study ID

48235

DARWIN EU® study

No

Study countries

☐ Japan

Study description

This investigation will be conducted to collect and evaluate information regarding the safety and efficacy of ANORO ELLIPTA under the actual post-marketing use conditions of the product.

Study status

Finalised

Research institutions and networks

Institutions

[GlaxoSmithKline \(GSK\)](#)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

[Iwamizawa Municipal General Hospital Iwamizawa,
Japan](#)

Contact details

Study institution contact

GSK Clinical Disclosure Advisor GSK Clinical Disclosure
Advisor Pharma.CDR@gsk.com

Study contact

Pharma.CDR@gsk.com

Primary lead investigator

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 15/03/2013

Actual: 15/03/2013

Study start date

Planned: 20/02/2015

Actual: 20/02/2015

Data analysis start date

Actual: 03/07/2019

Date of final study report

Planned: 31/12/2019

Actual: 31/10/2019

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

GlaxoSmithKline

Study protocol

[gsk-200311-protocol-redact.pdf](#) (205.63 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Effectiveness study (incl. comparative)

Data collection methods:

Primary data collection

Main study objective:

This investigation will be conducted to collect and evaluate information regarding the safety and efficacy of ANORO ELLIPTA under the actual post-marketing use conditions of the product.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Non interventional, Observational Post Marketing Surveillance under actual drug use condition.

Study drug and medical condition

Medicinal product name

ANORO ELLIPTA

Population studied

Short description of the study population

This investigation will be conducted in patients who are first prescribed Anoro for the approved indication of the product, "Relief of symptoms of obstructive

airway disorder due to COPD (chronic bronchitis and emphysema) (in the case that long-acting inhaled anticholinergic and long-acting inhaled beta2-agonist combination is required)”.

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Special population of interest

Hepatic impaired

Pregnant women

Renal impaired

Estimated number of subjects

2000

Study design details

Outcomes

Information regarding the safety and efficacy of ANORO ELLIPTA under the actual post-marketing use conditions of the product.

Data analysis plan

Items related to patient disposition
Patient demographic and baseline characteristics
Items related to safety
Items related to efficacy

Documents

Study results

[gsk-200311-clinical-study-report-redact.pdf](#) (1.74 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No